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The diagnosis of cirrhosis: clinical relevance and methodology 
Solko W. Schalm 
Department of Hepatogastroenterology and Internal Medicine, Erasmus University Hospital -- Dijkzigt, Rotterdam, The Netherlands 
C IRRHOSIS is defined as a diffuse process character- ized by fibrosis and alteration of normal liver 
architecture into structurally abnormal nodules of liver 
cells surrounded by fibrosis (1). The diagnosis of cir- 
rhosis by liver biopsy is made if the biopsy contains 
at least one nodule completely surrounded by fibrosis 
tissue; large fibrous septae with absence of portal 
tracts, altered hepatic architecture and loss of vascular 
relationships are features suggestive of, but not diag- 
nostic for cirrhosis (1). 
Cirrhosis is usually divided into compensated and 
decompensated cirrhosis. In the latter stage, patients 
are symptomatic, with jaundice, ascites, variceal bleed- 
ing, or encephalopathy; the clinical significance of this 
stage needs little discussion in view of its high l-year 
mortality. Consideration of liver transplantation is de- 
sirable in this group, especially if the etiology of the 
liver disease indicates that it is not amenable to medical 
therapy. 
The clinical significance of compensated cirrhosis is 
less well recognized, as more than 70% of patients are 
asymptomatic (2). Such patients often have diseases 
such as chronic hepatitis B, chronic hepatitis C or 
autoimmune hepatitis. 
In the nineties, it has become increasingly apparent 
that the stage of cirrhosis is a key factor for defining 
prognosis and management; this is similar to the situ- 
ation in the seventies when the etiology of the liver dis- 
ease emerged as a clinically important factor for prog- 
nosis and response to therapy (3). With regard to prog- 
nosis, mortality in long-term follow-up studies of 
‘chronic active hepatitis’ is confined mainly to patients 
with cirrhosis at entry (4). A recent study of a cohort 
of more than 200 patients with primary intrahepatic 
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cholangitis (PBC) treated with ursodeoxycholic acid 
for 5 years confirmed the finding that mortality and 
clinical complications of liver disease occurred pre- 
dominantly in those with cirrhosis (5). 
In relation to response to therapy, two recent con- 
sensus reports on the management of chronic hepatitis 
C recommended alfa interferon therapy for patients 
with active disease and signs of progression (fibrosis), 
but not for patients with cirrhosis (6,7). The biological 
basis for the recommendation is the significantly lower 
response to alfa interferon in cirrhosis. 
Concerning monitoring, the diagnosis of cirrhosis in 
a patient with chronic liver disease is nowadays of clin- 
ical significance for those patients who elect to partici- 
pate in screening programs for detection of hepatocel- 
lular carcinoma (8). 
In view of the increasing clinical importance of the 
diagnosis of cirrhosis in the asymptomatic patient, it 
is disheartening to realize that diagnostic accuracy in 
routine clinical practice is rather poor. While we re- 
quire a sensitivity of more than 95% for etiologic tests 
like HBsAg and anti-HCV, we commonly use method- 
ology (percutaneous liver biopsy) with a sensitivity of 
below 80% in detecting cirrhosis. The diagnostic sensi- 
tivity can be increased by examining more than one 
biopsy specimen (9,lO) or by combining liver biopsy 
with laparoscopy (1 l), but neither approach has found 
general acceptance in routine clinical practice. 
The paper by Gaiani et al. (12) in this issue of the 
Journal may provide a solution to the clinical dilemma 
of diagnosing cirrhosis. They performed abdominal ul- 
trasound prior to taking a percutanous liver biopsy in 
212 patients with chronic liver disease without clinical 
signs suggestive of cirrhosis. The diagnosis of cirrhosis 
was made in 47 patients by histology, and in 69 patients 
by ultrasound. The histological criteria for cirrhosis 
were based on the international standard; the ultra- 
sound criteria for cirrhosis were initially based on a 
score to which 7 parameters contributed. After com- 
pletion of the study, it was found that only two ultra- 
sound variables, liver surface nodularity and portal 
vein mean flow velocity, made independent contri- 
butions to the diagnosis. 
In 37 patients, histology and ultrasound were con- 
cordant in the diagnosis of cirrhosis. In 10 patients cir- 
rhosis was found on histology, but ultrasound showed 
no conclusive evidence (false-negative ultrasound). In 32 
patients, ultrasound indicated cirrhosis, but histology 
was not diagnostic. The authors correctly stated that it 
is not clear whether ultrasound overestimates the diag- 
nosis of cirrhosis, or histology underestimates it. How- 
ever, there is convincing evidence that overestimation of 
the diagnosis of cirrhosis by ultrasound is unlikely: 
The key element in the ultrasound diagnosis is the 
nodularity of the liver surface; 
Clinical and biochemical signs of liver cirrhosis de- 
veloped with equal frequency during 6 months of 
follow-up in patients with histologic cirrhosis, as in 
patients with cirrhosis based on ultrasound only; 
In 29 out of 32 patients with cirrhosis based on ul- 
trasound only, the histology showed sample frag- 
mentation, advanced fibrosis, and architectural dis- 
tinction, but no well-defined nodules. 
Thus, assuming that at least 29 patients with a diag- 
nosis of cirrhosis by ultrasound did in fact have cir- 
rhosis, the real number of patients with cirrhosis in the 
cohort was at least 76. So, the prevalence of cirrhosis 
in the cohort was 36% (76/212), instead of 22% (47/ 
212). Standard calculations then revealed a diagnostic 
sensitivity of 62% for percutaneous liver biopsy, and 
87% for ultrasound; specificities for both methods are 
98% or more. 
The gold standard for the diagnosis of cirrhosis in 
hepatology is the liver biopsy. In view of these find- 
ings, do we need to adapt? The design of Gaiani’s 
study was excellent, with a training and a validation 
sample. The statistical analysis evaluated the contri- 
bution of each element of the ultrasound score, and 
defined the two independent variables with key prog- 
nostic information. The study confirms the under- 
estimation of the diagnosis of cirrhosis by a single 
specimen. Therefore, in view of the clinical import- 
ance of making the diagnosis of cirrhosis, we need to 
adapt our procedures. 
What should become the routine clinical practice? 
Prior to performing a liver biopsy, ultrasound should 
be done by an operator trained to assess liver surface 
nodularity and possibly portal vein mean flow velocity 
The result should be available at the time of liver bi- 
opsy. If cirrhosis is suspected from the ultrasound or 
the clinical evaluation, at least two separate specimens 
should be obtained for standard histological elevation. 
If histology shows no cirrhosis (nodules surrounded by 
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fibrosis), but shows fragmentation, fibrosis, and archi- 
tectural distortion, the diagnosis of cirrhosis should 
still be made if there is ultrasound diagnosis of cir- 
rhosis. It is to be hoped that this approach will elimin- 
ate histological diagnosis as early, beginning, possible 
and probable cirrhosis. Hepatologists now have a re- 
fined set of tests to unravel the etiology of liver disease; 
the time has come to improve our methods for deter- 
mining the stage of the liver disease, specifically the 
diagnosis of cirrhosis. 
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